Wednesday, 18 Oct 2017

You are here

ACR/AAHKS Guidelines on Perioperative Management

The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total joint replacement.

A multidisciplinary panel of orthopedists, rheumatologists and patients reviewed the available evidence regarding the safety of steroid, DMARD or biologic perioperatively, with the primary goal being the reduction in infectious risk and perioperative infections. The recommendations are primarily expert opinion with some guidance from prior studies.

The ACR published these new ACR/AAHKS guidelines on its website (Citation source: http://buff.ly/2rSoja8 ).

These are intened to aid the managment of patients with inflammatory rheumatic diseasea undergoing total knee arthroplasty (TKA) or total hip arthroplasty (THA).

The guidelines discuss perioperative management of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE).

These guidelines specifically address the use of corticosteroids, DMARDs, biologic agents, and tofacitinib.

7 Primary Recommendations Governing Anti-Rheumatic Drug Use in Rheumatic disease Patients Undergoing Elective THA or TKA:

  1. Nonbiologic-DMARDs should be continued in the during and throughout the perioperative period for patients TKA or THA.
  2. Biologic therapies should be withheld for surgery and prior to surgery, biologics should be held for one-dosing cycle or surgery should be planned for the end of the dosing cycle. of that medication.
  3. Tofacitinib be withheld 7 days before surgery in patients with RA, SpA and JIA.
  4. Severe SLE patients: continue methotrexate, mycophenolate mofetil, azathioprine, cyclosporine or tacrolimus in cases with severe SLE through the surgical period.
  5. However, non-severe SLE: mycophenolate mofetil, azathioprine, cyclosporine or tacrolimus should be withheld 1 week before patients undergo total joint replacement.
  6. Biologic therapy that was withheld prior to surgery should be re-started with evidence of wound healing and no sign of infection or drainage (~14 days).
  7. There is no need/utility to "stress dose steroids" for those on chronic steroids; the panel recommended the continued use of daily dose of glucocorticoids for patients throughout surgery.

The evidence for each of these was low as there are few if any well designed trials to answer these questions conclusively.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs wherever nitric oxide is produced in abundance.

2016 EULAR Guidelines on RA Management

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.

New EULAR Guidelines for Ultrasound Use

In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.

The Unregulated $37 Billion Supplement Industry

In 1994 there were 600 supplement companies, producing 4,000 OTC supplement products for a total revenue of about $4 billion. Today we have close to 6,000 companies, producting nearly 75,000 supplement products, bringing in $37 billion annually.  And all of this is regulated by 26 people and a budget of $5 million at the FDA.

Curbside Consults - July 2017

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases.